Statins and the role of nitric oxide in chronic heart failure

Stephan Von Haehling, Stefan D. Anker, Eberhard Bassenge

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Endothelial dysfunction plays an important role in a number of cardiovascular diseases. An important pathogenetic factor for the development of endothelial dysfunction is lack of nitric oxide (NO), which is a potent endothelium-derived vasodilating substance. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), originally designed to lower plasma cholesterol levels, seem to ameliorate endothelial dysfunction by a mechanism so far only partly understood. However, statins increase nitric oxide synthase activity. It has been speculated that this and other "side effects" of statin treatment are due to inhibition of Rho, an intracellular signalling protein that initiates Rho kinase transcription. Moreover, statins possess anti-inflammatory characteristics. Some statins have proven to lower plasma levels of C-reactive protein, which is induced by pro-inflammatory cytokines. Other statins have been demonstrated to directly inhibit pro-inflammatory cytokine induction. Finally, some data suggest that statins might be able to counterbalance an increased production of oxygen free radicals. Since chronic heart failure is accompanied not only by endothelial dysfunction, but also by pro-inflammatory cytokine activation and enhanced formation of oxygen free radicals, it is tempting to speculate that statins might be an ideal candidate to treat certain features of this disease. The doses needed to achieve the desired effects might be much lower than those needed to treat hypercholesterolemia.

Original languageEnglish
Pages (from-to)99-106
Number of pages8
JournalHeart Failure Reviews
Volume8
Issue number1
DOIs
Publication statusPublished - Jan 2003

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Nitric Oxide
Heart Failure
Cytokines
Free Radicals
Reactive Oxygen Species
Intracellular Signaling Peptides and Proteins
rho-Associated Kinases
Hypercholesterolemia
Nitric Oxide Synthase
C-Reactive Protein
Endothelium
Oxidoreductases
Anti-Inflammatory Agents
Cardiovascular Diseases
Cholesterol

Keywords

  • Chronic heart failure
  • Endothelial dysfunction
  • Nitric oxide
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Statins and the role of nitric oxide in chronic heart failure. / Von Haehling, Stephan; Anker, Stefan D.; Bassenge, Eberhard.

In: Heart Failure Reviews, Vol. 8, No. 1, 01.2003, p. 99-106.

Research output: Contribution to journalArticle

Von Haehling, Stephan ; Anker, Stefan D. ; Bassenge, Eberhard. / Statins and the role of nitric oxide in chronic heart failure. In: Heart Failure Reviews. 2003 ; Vol. 8, No. 1. pp. 99-106.
@article{09f40133c11842e5aeb1bed4bdcef2f0,
title = "Statins and the role of nitric oxide in chronic heart failure",
abstract = "Endothelial dysfunction plays an important role in a number of cardiovascular diseases. An important pathogenetic factor for the development of endothelial dysfunction is lack of nitric oxide (NO), which is a potent endothelium-derived vasodilating substance. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), originally designed to lower plasma cholesterol levels, seem to ameliorate endothelial dysfunction by a mechanism so far only partly understood. However, statins increase nitric oxide synthase activity. It has been speculated that this and other {"}side effects{"} of statin treatment are due to inhibition of Rho, an intracellular signalling protein that initiates Rho kinase transcription. Moreover, statins possess anti-inflammatory characteristics. Some statins have proven to lower plasma levels of C-reactive protein, which is induced by pro-inflammatory cytokines. Other statins have been demonstrated to directly inhibit pro-inflammatory cytokine induction. Finally, some data suggest that statins might be able to counterbalance an increased production of oxygen free radicals. Since chronic heart failure is accompanied not only by endothelial dysfunction, but also by pro-inflammatory cytokine activation and enhanced formation of oxygen free radicals, it is tempting to speculate that statins might be an ideal candidate to treat certain features of this disease. The doses needed to achieve the desired effects might be much lower than those needed to treat hypercholesterolemia.",
keywords = "Chronic heart failure, Endothelial dysfunction, Nitric oxide, Statin",
author = "{Von Haehling}, Stephan and Anker, {Stefan D.} and Eberhard Bassenge",
year = "2003",
month = "1",
doi = "10.1023/A:1022103222857",
language = "English",
volume = "8",
pages = "99--106",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Statins and the role of nitric oxide in chronic heart failure

AU - Von Haehling, Stephan

AU - Anker, Stefan D.

AU - Bassenge, Eberhard

PY - 2003/1

Y1 - 2003/1

N2 - Endothelial dysfunction plays an important role in a number of cardiovascular diseases. An important pathogenetic factor for the development of endothelial dysfunction is lack of nitric oxide (NO), which is a potent endothelium-derived vasodilating substance. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), originally designed to lower plasma cholesterol levels, seem to ameliorate endothelial dysfunction by a mechanism so far only partly understood. However, statins increase nitric oxide synthase activity. It has been speculated that this and other "side effects" of statin treatment are due to inhibition of Rho, an intracellular signalling protein that initiates Rho kinase transcription. Moreover, statins possess anti-inflammatory characteristics. Some statins have proven to lower plasma levels of C-reactive protein, which is induced by pro-inflammatory cytokines. Other statins have been demonstrated to directly inhibit pro-inflammatory cytokine induction. Finally, some data suggest that statins might be able to counterbalance an increased production of oxygen free radicals. Since chronic heart failure is accompanied not only by endothelial dysfunction, but also by pro-inflammatory cytokine activation and enhanced formation of oxygen free radicals, it is tempting to speculate that statins might be an ideal candidate to treat certain features of this disease. The doses needed to achieve the desired effects might be much lower than those needed to treat hypercholesterolemia.

AB - Endothelial dysfunction plays an important role in a number of cardiovascular diseases. An important pathogenetic factor for the development of endothelial dysfunction is lack of nitric oxide (NO), which is a potent endothelium-derived vasodilating substance. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), originally designed to lower plasma cholesterol levels, seem to ameliorate endothelial dysfunction by a mechanism so far only partly understood. However, statins increase nitric oxide synthase activity. It has been speculated that this and other "side effects" of statin treatment are due to inhibition of Rho, an intracellular signalling protein that initiates Rho kinase transcription. Moreover, statins possess anti-inflammatory characteristics. Some statins have proven to lower plasma levels of C-reactive protein, which is induced by pro-inflammatory cytokines. Other statins have been demonstrated to directly inhibit pro-inflammatory cytokine induction. Finally, some data suggest that statins might be able to counterbalance an increased production of oxygen free radicals. Since chronic heart failure is accompanied not only by endothelial dysfunction, but also by pro-inflammatory cytokine activation and enhanced formation of oxygen free radicals, it is tempting to speculate that statins might be an ideal candidate to treat certain features of this disease. The doses needed to achieve the desired effects might be much lower than those needed to treat hypercholesterolemia.

KW - Chronic heart failure

KW - Endothelial dysfunction

KW - Nitric oxide

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=0037235770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037235770&partnerID=8YFLogxK

U2 - 10.1023/A:1022103222857

DO - 10.1023/A:1022103222857

M3 - Article

C2 - 12652163

AN - SCOPUS:0037235770

VL - 8

SP - 99

EP - 106

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 1

ER -